Lorenil*3 Capsule Molli Vaginali 200mg


SKU: fb908febdc94 Category:


Description Lorenil * 3 Vaginal soft capsules 200mgDenomination: Lorenil Vaginal soft capsules
Pharmacotherapeutic category: antimicrobials and antiseptic, excluding associations with corticosteroids.
Active principles: nitrate fisticonazole.
Excipients: vaginal soft capsules 200 mg: triglycerides of saturated fatty acids; Anhydrous colloidal silica. Casing welcoming: jelly; glycerol or; titanium dioxide; sodium ethylidrossiibenzoate; sodium propilidrossiibenzooto.capsules vaginal soft 600 mg: liquid paraffin; white vaseline; soy lecithin; jelly; glycerol; titanium dioxide; sodium ethylidrossiibenzoate; Sodium propylidrossiibenzoate.
Directions: candidiasis of genital mucous membranes (vulvovaginiti, affected, infectious fluor).
Contraindications / EFF.Secondar: hypersensitivity to the active ingredient or to any of the excipients.
Posology: Vaginal soft capsules: 1 Vaginal soft capsule from 200 mg in the evening before lying for 3 days or second of the doctor’s judgment.1 Vaginal soft capsule from 600 mg in the evening in unique administration. In case of persistence of symptomatology, after three Days can be repeated a second administration. The soft capsules must be introduced deeply into the vagina up to the level of the supplies.
Storage: Do not store at a temperature higher than 30 degrees C.
Warnings: use, especially prolonged products, products for topical use, can give rise to sensitization phenomena. At the time of intravoginal introduction you can encounter a modest burning sensation that disappears quickly.
Interactions: Not known.
Unwanted effects: the medicine is generally well tolerated on mucous membranes; Only exceptionally mild and transitional reactions erythematous reactions have been reported. Systemic character.
Pregnancy and lactation: Although the absorption of the medicinal product is poor, the use of the urante product pregnancy and breastfeeding is not recommended except in particular cases and after a careful assessment of the benefit / risk report.